| Oral selinexor–dexamethasone for triple-class refractory multiple myeloma A Chari, DT Vogl, M Gavriatopoulou, AK Nooka, AJ Yee, CA Huff, ... New England Journal of Medicine 381 (8), 727-738, 2019 | 635 | 2019 |
| Triplet therapy, transplantation, and maintenance until progression in myeloma PG Richardson, SJ Jacobus, EA Weller, H Hassoun, S Lonial, NS Raje, ... New England Journal of Medicine 387 (2), 132-147, 2022 | 292 | 2022 |
| Frataxin activates mitochondrial energy conversion and oxidative phosphorylation M Ristow, MF Pfister, AJ Yee, M Schubert, L Michael, CY Zhang, K Ueki, ... Proceedings of the National Academy of Sciences 97 (22), 12239-12243, 2000 | 284 | 2000 |
| Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial AJ Yee, WI Bensinger, JG Supko, PM Voorhees, JG Berdeja, ... The Lancet Oncology 17 (11), 1569-1578, 2016 | 194 | 2016 |
| Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma DT Vogl, D Dingli, RF Cornell, CA Huff, S Jagannath, D Bhutani, J Zonder, ... Journal of clinical oncology 36 (9), 859-866, 2018 | 171 | 2018 |
| A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant‐ineligible multiple myeloma EK O'Donnell, JP Laubach, AJ Yee, T Chen, CA Huff, FG Basile, ... British journal of haematology 182 (2), 222-230, 2018 | 166 | 2018 |
| Genetic interrogation of circulating multiple myeloma cells at single-cell resolution JG Lohr, S Kim, J Gould, B Knoechel, Y Drier, MJ Cotton, D Gray, N Birrer, ... Science translational medicine 8 (363), 363ra147-363ra147, 2016 | 146 | 2016 |
| Ricolinostat (ACY‐1215) induced inhibition of aggresome formation accelerates carfilzomib‐induced multiple myeloma cell death Y Mishima, L Santo, H Eda, D Cirstea, N Nemani, AJ Yee, E O'Donnell, ... British journal of haematology 169 (3), 423-434, 2015 | 146 | 2015 |
| Plasma cell disorders AJ Yee, T Hideshima, N Raje, KC Anderson Holland‐Frei Cancer Medicine, 1-30, 2016 | 110 | 2016 |
| Human cochlear expressed sequence tags provide insight into cochlear gene expression and identify candidate genes for deafness AB Skvorak, Z Weng, AJ Yee, NG Robertson, CC Morton Human molecular genetics 8 (3), 439-452, 1999 | 98 | 1999 |
| Myeloma and bone disease C Panaroni, AJ Yee, NS Raje Current osteoporosis reports 15, 483-498, 2017 | 97 | 2017 |
| Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials M Gavriatopoulou, A Chari, C Chen, N Bahlis, DT Vogl, A Jakubowiak, ... Leukemia 34 (9), 2430-2440, 2020 | 84 | 2020 |
| Assessment of safety and immunogenicity of PVX-410 vaccine with or without lenalidomide in patients with smoldering multiple myeloma: a nonrandomized clinical trial AK Nooka, ML Wang, AJ Yee, JL Kaufman, J Bae, D Peterkin, ... JAMA oncology 4 (12), e183267-e183267, 2018 | 82 | 2018 |
| Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia JJ Castillo, K Meid, JN Gustine, C Leventoff, T White, CA Flynn, ... Leukemia 36 (2), 532-539, 2022 | 72 | 2022 |
| Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients AJ Yee, NS Raje Clinical interventions in aging, 331-338, 2012 | 71 | 2012 |
| Early detection of multiorgan light-chain amyloidosis by whole-body 18F-florbetapir PET/CT EC Ehman, MS El-Sady, MF Kijewski, YM Khor, S Jacob, FL Ruberg, ... Journal of Nuclear Medicine 60 (9), 1234-1239, 2019 | 70 | 2019 |
| Panobinostat and multiple myeloma in 2018 AJ Yee, NS Raje The oncologist 23 (5), 516-517, 2018 | 67 | 2018 |
| Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients A Jurczyszyn, J Radocha, J Davila, MA Fiala, A Gozzetti, N Grząśko, ... British Journal of Haematology 180 (6), 831-839, 2018 | 64 | 2018 |
| Successful anti‐CD19 CAR T‐cell therapy in HIV‐infected patients with refractory high‐grade B‐cell lymphoma JS Abramson, KE Irwin, MJ Frigault, J Dietrich, B McGree, JT Jordan, ... Cancer 125 (21), 3692-3698, 2019 | 55 | 2019 |
| Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-cell maturation antigen (BCMA) x CD3 T-cell engager (TCE), in patients (pts) with relapsed/refractory multiple myeloma (RRMM … SW Wong, N Bar, L Paris, CC Hofmeister, M Hansson, A Santoro, ... Blood 140 (Supplement 1), 400-402, 2022 | 54 | 2022 |
